Kubera Health | $6,500,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Volt Harbor Inc. | $2,000,000 | (May 29, 2026)
Pinnacle Medicines
- 27/03/2026
- Series B
- $89,000,000
Pinnacle Medicines is an emerging peptide drug discovery company based in Doylestown, Pennsylvania. Pinnacle has raised substantial Series A funding led by OrbiMed and Qiming Venture Partners, with the goal to discover first and best-in-class peptide therapeutics. The highly accomplished and experienced team at Pinnacle will utilize their deep know-how in peptide drug discovery, pioneering structure and AI-based drug design tools to realize the full potential of peptide modality as safe, effective and convenient therapeutics for unmet medical needs.
- Industry Biotechnology Research
- Website https://www.pinnaclemedicines.com/language/en/index.php
- LinkedIn https://www.linkedin.com/company/pinnaclemed/
Related People
Chengzao SunCo Founder
United States -
Warrington, Pennsylvania
0+ years in peptide drug discovery and development at Amylin, BMS, Merck, and Janssen
Team and capability building, internal and external budget and resource managing
Project chemistry leader in identifications of 1 Ph2b, 1 Ph1, 2 NME and 2 late lead candidates
Drug product leader on 2 Ph2-3, 1 Ph1 and 1 preclinic candidates
Expertise in oral and injectable macrocyclic, long linear peptide and peptide conjugates, across discovery to Ph3 including IND, CMC, drug product, clinical protocol.
Countable Labs | $26,000,000 | (May 29, 2026)
Solstice | $21,000,000 | (May 29, 2026)
Rep AI | $6,200,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)
Blulabs | $7,000,000 | (May 29, 2026)
allO | $14,000,000 | (May 29, 2026)